These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38451075)

  • 1. Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
    Akingbemi W; Kurtz G; Yegya-Raman N; Plastaras JP; Schuster SJ; Chong EA
    Leuk Lymphoma; 2024 Jun; 65(6):860-863. PubMed ID: 38451075
    [No Abstract]   [Full Text] [Related]  

  • 2. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
    Frigault MJ; Dietrich J; Martinez-Lage M; Leick M; Choi BD; DeFilipp Z; Chen YB; Abramson J; Crombie J; Armand P; Nayak L; Panzini C; Riley LS; Gallagher K; Maus MV
    Blood; 2019 Sep; 134(11):860-866. PubMed ID: 31320380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
    Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
    Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
    Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
    Front Immunol; 2021; 12():693200. PubMed ID: 34290712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
    Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
    Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
    Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
    Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma knife stereotactic radiosurgery as an effective tool in primary CNS lymphoma: Evaluation of stereotactic radiosurgery and methotrexate treatment in a prospective and observational clinical research study.
    Alvarez-Pinzon AM; Wolf A; Valerio JE; Borro M; Herrera D; Alonso JR
    Clin Neurol Neurosurg; 2021 Feb; 201():106457. PubMed ID: 33418336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma after liver transplantation treated by radiosurgery combined with fractionated radiotherapy.
    Kim MS; Lee JI; Kim WS; Ko YH
    J Clin Neurosci; 2009 Apr; 16(4):583-5. PubMed ID: 19200738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.
    Ahmed G; Alsouqi A; Szabo A; Samples L; Shadman M; Awan FT; Rojek AE; Riedell PA; Iqbal M; Fenske TS; Kharfan-Dabaja MA; Ito S; Hamadani M
    Blood Adv; 2024 Jul; 8(13):3528-3531. PubMed ID: 38701405
    [No Abstract]   [Full Text] [Related]  

  • 10. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
    Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
    Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for central nervous system lymphomas in immunocompetent patients.
    Jahnke K; Thiel E
    Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
    Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
    Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
    Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
    [No Abstract]   [Full Text] [Related]  

  • 14. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
    Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
    Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
    J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphoma as a neurosurgical problem.
    Szczepanek D; Wąsik-Szczepanek E; Stoma F; Sokołowska B; Trojanowski T
    Neurol Neurochir Pol; 2017; 51(4):319-323. PubMed ID: 28476199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
    Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
    Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
    [No Abstract]   [Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
    Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
    Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
    Front Immunol; 2022; 13():965224. PubMed ID: 36059496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.
    Wu J; Meng F; Cao Y; Zhang Y; Zhu X; Wang N; Wang J; Huang L; Zhou J; Xiao Y
    Blood Cancer J; 2021 Jul; 11(7):131. PubMed ID: 34267187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.